Advertisement

Hypovitaminosis D in the elderly: From bone to brain

  • E. P. CherniackEmail author
  • H. Florez
  • B. A. Roos
  • B. R. Troen
  • S. Levis
Nutrition

Conclusion

There is a growing consensus that vitamin D recommended daily intakes for the elderly are far too low, and that all individuals should take as much vitamin D as needed to raise levels to between 32 to 40 ng/ml (80 to 100 nmol/L) (5, 108, 109). Supplementation will likely be necessary in most elderly, since according to current lifestyles, diet and sunlight alone are inadequate sources of vitamin D (17). We believe that to raise and maintain 25(OH) vitamin D levels at a minimum of 32 ng/ml (80 nmol/L), most elderly will require at least 2,000 IU of cholecalciferol per day.

But many questions remain. Are other biological markers preferable to 25(OH) vitamin D to assess repletion? Do the current estimates of optimal serum levels provide health benefits for all conditions, or do optimal vitamin D levels differ depending on the target tissue? How much vitamin D, cholecalciferol, or ergocalciferol, should be given to maintain these levels? What are the molecular mechanisms by which vitamin D influences health and disease?

Cross-sectional studies have suggested that low vitamin D levels not only predict nursing home admission but also are associated with increased mortality (1, 2). Further knowledge of the mechanisms of vitamin D action and prospective clinical trials designed to determine if supplementation resulting in vitamin D levels higher than those shown to reduce the risk of falls and fractures is also effective in reducing the burden of various medical conditions could help validate a cost-effective intervention that will provide greater quality of life and longevity and have a major public health impact.

Keywords

Predict Nursing Home Admission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. Sep 10 2007;167(16): 1730–1737.PubMedGoogle Scholar
  2. 2.
    Visser M, Deeg DJ, Puts MT, Scidell JC, Lips P. Low serum concentrations of 25-hydroxy vitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr. Sep 2006; 84(3): 616–622; quiz 671–612.PubMedGoogle Scholar
  3. 3.
    Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. Dec 2004;80(6 Suppl): 1706S-1709S.PubMedGoogle Scholar
  4. 4.
    Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. Oct 2005;97(l-2): 13–19.PubMedGoogle Scholar
  5. 5.
    Holick MF. The vitamin d epidemic and its health consequences. J Nutr. Nov 2005;135(11): 2739S-2748S.PubMedGoogle Scholar
  6. 6.
    Corless D, Boucher BJ, Cohen RD, Beer M, Gupta SP. Vitamin-D status in long-stay geriatric patients. Lancet. Jun 28 1975;1(7922): 1404–1406.PubMedGoogle Scholar
  7. 7.
    Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7(5): 439–443.PubMedGoogle Scholar
  8. 8.
    Kudlacek S, Schneider B, Peterlik M, et al. Assessment of vitamin D and calcium status in healthy adult Austrians. Eur J Clin Invest. Apr 2003;33(4): 323–331.PubMedGoogle Scholar
  9. 9.
    Nakamura K, Nishiwaki T, Ueno K, Yamamoto M. Serum 25-hydroxyvitamin D levels and activities of daily living in noninstitutionalized elderly Japanese requiring care. J Bone Miner Metab. 2005;23(6): 488–494.PubMedGoogle Scholar
  10. 10.
    Levis S, Gomez A, Jimenez C, et al. Vitamin d deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab. Mar 2005;90(3): 1557–1562.PubMedGoogle Scholar
  11. 11.
    Vecino-Vecino C, Gratton M, Kremer R, Rodriguez-Manas L, Duque G. Seasonal variance in serum levels of vitamin d determines a compensatory response by parathyroid hormone: study in an ambulatory elderly population in Quebec. Gerontology. 2006;52(1): 33–39.PubMedGoogle Scholar
  12. 12.
    Meier C, Woitge HW, Witte K, Lemmer B, Scibel MJ. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res. Aug 2004; 19(8): 1221–1230.PubMedGoogle Scholar
  13. 13.
    Gannage-Yared MH, Chemali R, Yaacoub N, Halaby G. Hypovitaminosis D in a sunny country: relation to lifestyle and bone markers. J Bone Miner Res. Sep 2000; 15(9): 1856–1862.PubMedGoogle Scholar
  14. 14.
    Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitaminD. Arch Dermatol. Apr 1991;127(4): 536–538.PubMedGoogle Scholar
  15. 15.
    Grieger JA, Nowson CA. Nutrient intake and plate waste from an Australian residential care facility. Eur J Clin Nutr. Dec 6 2006.Google Scholar
  16. 16.
    Dumartheray EW, et al. Enery and nutrient intake of Swiss women aged 75–87 years. J Hum Nutr Diet. 2006; 19: 431–435.PubMedGoogle Scholar
  17. 17.
    Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. Feb 2005; 135(2): 317–322.PubMedGoogle Scholar
  18. 18.
    McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. Am J Med. Jul 1992;93(1): 69–77.PubMedGoogle Scholar
  19. 19.
    Itonaga I, Sabokbar A, Neale SD, Athanasou NA. 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. Biochem Biophys Res Commun. 1999;264(2): 590–595.PubMedGoogle Scholar
  20. 20.
    Kew RR, Fisher JA, Webster RO. Co-chemotactic effect of Gc-globulin (vitamin D binding protein) for C5a. Transient conversion into an active co-chemotaxin by neutrophils. J Immunol. Dec 1 1995; 155(11): 5369–5374.PubMedGoogle Scholar
  21. 21.
    Adams JS. Vitamin D as a defensin. J Musculoskelet Neuronal Interact. Oct-Dec 2006;6(4): 344–346.PubMedGoogle Scholar
  22. 22.
    Shah AB, DiMartino SJ, Trujillo G, Kew RR. Selective inhibition of the C5a chemotactic cofactor function of the vitamin D binding protein by 1,25(OH)2 vitamin D3. Mol Immunol. Mar 2006;43(8): 1109–1115.PubMedGoogle Scholar
  23. 23.
    Bogaerts I, Verboven C, Van Baelen H, Bouillon R. New Aspects of DBP. In: Fedelman D, Pike JE, Glorieux FH, eds. Vitamin D. Burlington, MA: Elsevier Academic Press; 2005: 146.Google Scholar
  24. 24.
    Henry H. The 25-hydroxyvitamin D la-hydroxylase. In: Feldman D, Pike JW, Gloreiux FH, eds. Vitamin D. Burlington, MA: Elsevier Academic Press; 2005.Google Scholar
  25. 25.
    Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. Oct 2005; 14(10): 2335–2339.PubMedGoogle Scholar
  26. 26.
    Grundberg E, Lau EM, Pastinen T, et al. Vitamin D receptor 3’ haplotypes are unequally expressed in primary human bone cells and associated with increased fracture risk: the MrOS Study in Sweden and Hong Kong. J Bone Miner Res. Jun 2007;22(6): 832–840.PubMedGoogle Scholar
  27. 27.
    de Souza CM, Braosi AP, Luczyszyn SM, et al. Association between vitamin D receptor gene polymorphisms and susceptibility to chronic kidney disease and periodontitis. Blood Purif. 2007;25(5-6): 411–419.PubMedGoogle Scholar
  28. 28.
    Parfitt AM. Osteomalacia and related disorders. In: Avioli LV, Krane SM, eds. Metabolic bone disease and clinical related disorders. Second ed. Philadelphia: WB Saunders; 1990: 329–396.Google Scholar
  29. 29.
    Heaney RP. Lessons for nutritional science from vitamin D. Am J Clin Nutr. May 1999; 69(5): 825–826.PubMedGoogle Scholar
  30. 30.
    Cherniack EP, Troen BR. Calciotropic Hormones. In: Duque G, Kiel DP, eds. Senile Osteoporosis: Advances in Pathophysiology and Therapeutic Approach. London: Springer-Verlag; 2008: 34–46.Google Scholar
  31. 31.
    Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. Jan 2003;88(1): 185–191.PubMedGoogle Scholar
  32. 32.
    Souberbielle JC, Cormier C, Kindermans C, et al. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab. Jul 2001;86(7): 3086–3090.PubMedGoogle Scholar
  33. 33.
    Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas. Mar 15 1999;31(3): 207–219.PubMedGoogle Scholar
  34. 34.
    Holick MF, Siris ES, Binkley N, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. Jun 2005;90(6): 3215–3224.PubMedGoogle Scholar
  35. 35.
    Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. Mar 19 1998;338(12): 777–783.PubMedGoogle Scholar
  36. 36.
    Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am JMed. Jun 1 2002; 112(8): 659–662.Google Scholar
  37. 37.
    Maggjo D, Cherubini A, Lauretani F, et al. 25(OH)D Serum levels decline with age earlier in women than in men and less efficiently prevent compensatory hyperparathyroidism in older adults. J Gerontol A Biol Sci Med Sci. Nov 2005;60(11): 1414–1419.Google Scholar
  38. 38.
    Fisher AA, Davis MW. Is the current anti-osteoporotic therapy paradigm good enough? J Am Geriatr Soc. Dec 2006;54(12): 1960–1961, author reply 1961–1963.PubMedGoogle Scholar
  39. 39.
    Sahota O, Gaynor K, Harwood RH, Hosking DJ. Hypovitaminosis D and ‘functional hypoparathyroidism’-the NoNoF (Nottingham Neck of Femur) study. Age Ageing. Nov 2001;30(6): 467–472.PubMedGoogle Scholar
  40. 40.
    Deplas A, Debiais F, Alcalay M, Bontoux D, Thomas P. Bone density, parathyroid hormone, calcium and vitamin D nutritional status of institutionalized elderly subjects. J Nutr Health Aging. 2004;8(5): 400–404.PubMedGoogle Scholar
  41. 41.
    Sahota O, Mundey MK, San P, Godber IM, Hosking DJ. Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int. 2006;17(7): 1013–1021.PubMedGoogle Scholar
  42. 42.
    Sahota O, Mundey MK, San P, Godber IM, Lawson N, Hosking DJ. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone. Jul 2004;35(1): 312–319.PubMedGoogle Scholar
  43. 43.
    Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. Bmj. Mar 1 2003;326(7387): 469.PubMedGoogle Scholar
  44. 44.
    Dawson-Hughes B, Harris SS, Krall EA, Dallai GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. Sep 4 1997;337(10): 670–676.PubMedGoogle Scholar
  45. 45.
    Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. Dec 3 1992;327(23): 1637–1642.PubMedGoogle Scholar
  46. 46.
    Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. Feb 16 2006;354(7): 669–683.PubMedGoogle Scholar
  47. 47.
    Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. Bmj. Apr 30 2005;330(7498): 1003.PubMedGoogle Scholar
  48. 48.
    Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. May 7–13 2005;365(9471): 1621–1628.PubMedGoogle Scholar
  49. 49.
    Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. Jama. May 11 2005;293(18): 2257–2264.PubMedGoogle Scholar
  50. 50.
    Ishijima M, Yamanaka M, Sakamoto Y, et al. Vitamin D Insufficiency Impairs the Effect of Alendronate for the Treatment of Osteoporosis in Postmenopausal Women. J Bone Miner Res. September, 2005 2005; 20(Suppl 1): S296.Google Scholar
  51. 51.
    Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr. Sep 2004;80(3): 752–758.PubMedGoogle Scholar
  52. 52.
    Wicherts IS, van Schoor NM, Boeke AJ, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. Jun 2007;92(6): 2058–2065.PubMedGoogle Scholar
  53. 53.
    Kenny AM, Biskup B, Robbins B, Marcella G, Burleson JA. Effects of vitamin D supplementation on strength, physical function, and health perception in older, community-dwelling men. J Am Geriatr Soc. Dec 2003;51(12): 1762–1767.PubMedGoogle Scholar
  54. 54.
    Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc. Sep 2003;51(9): 1219–1226.PubMedGoogle Scholar
  55. 55.
    Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. Feb 2004; 19(2): 265–269.PubMedGoogle Scholar
  56. 56.
    Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab. Dec 2003;88(12): 5766–5772.PubMedGoogle Scholar
  57. 57.
    Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. Dec 2002;57(12): M772–777.PubMedGoogle Scholar
  58. 58.
    Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med. Jan 14 2008; 168(1): 103–108.PubMedGoogle Scholar
  59. 59.
    Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents severe falls in elderly community-dwelling women: a pragmatic population-based 3-year intervention study. Aging Clin Exp Res. Apr 2005; 17(2): 125–132.PubMedGoogle Scholar
  60. 60.
    Flicker L, Maclnnis RJ, Stein MS, et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J Am Geriatr Soc. Nov 2005;53(11): 1881–1888.PubMedGoogle Scholar
  61. 61.
    Broe KEea. A Higher Dose of Vitamin D Reduces the Risk of Falls in Nursing Home Residents: A Randomized, Multiple-Dose Study. The American Geriatrics Society. 2007:1–6.Google Scholar
  62. 62.
    Law M, Withers H, Morris J, Anderson F. Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. Age Ageing. Sep 2006; 35(5): 482–486.PubMedGoogle Scholar
  63. 63.
    Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. Jama. Apr 28 2004;291(16): 1999–2006.PubMedGoogle Scholar
  64. 64.
    Dhesi JK, Jackson SH, Bearne LM, et al. Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing. Nov 2004;33(6): 589–595.PubMedGoogle Scholar
  65. 65.
    Pfeifer M, Dobnig H, Begerow B, Suppan K. Effects of Vitamin D and Calcium Supplementation on Falls and Parameters of Muscle Function — A prospective, randomized, double-blind, multi-center Study. Journal of Bone and Mineral Research. 2004.Google Scholar
  66. 66.
    Apperly FL. The relation of solar radiation to cancer mortality in North America. Cancer Research. 1941; 1: 191–195.Google Scholar
  67. 67.
    Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. Sep 1980;9(3): 227–231.PubMedGoogle Scholar
  68. 68.
    Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. Feb 2006; 96(2): 252–261.PubMedGoogle Scholar
  69. 69.
    Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol. Sep 2006;92(1): 65–79.PubMedGoogle Scholar
  70. 70.
    Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologie analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. Jul-Aug 2006;26(4A): 2687–2699.PubMedGoogle Scholar
  71. 71.
    Kricker A, Armstrong B. Does sunlight have a beneficial influence on certain cancers? Prog Biophys Mol Biol. Sep 2006;92(1): 132–139.PubMedGoogle Scholar
  72. 72.
    Beer TM, Javle MM, Ryan CW, et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. Apr 2007;59(5): 581–587.PubMedGoogle Scholar
  73. 73.
    Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. Jun 2007;85(6): 1586–1591.PubMedGoogle Scholar
  74. 74.
    Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst. Nov 7 2007;99(21): 1594–1602.PubMedGoogle Scholar
  75. 75.
    Garland CF, Grant WB, Mohr SB, Gorham ED, Garland FC. What is the dose-response relationship between vitamin D and cancer risk? Nutr Rev. Aug 2007;65(8 Pt 2): S91–95.PubMedGoogle Scholar
  76. 76.
    van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. Oct 2005;97(1-2): 93–101.PubMedGoogle Scholar
  77. 77.
    Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. Mar 24 2006; 311(5768): 1770–1773.PubMedGoogle Scholar
  78. 78.
    Cannell JJ, Zasloff M, Garland CF, Scragg R, Giovannucci E. On the epidemiology of influenza. Virol J. 2008;5: 29.PubMedGoogle Scholar
  79. 79.
    Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. Faseb J. Jul 2005; 19(9): 1067–1077.PubMedGoogle Scholar
  80. 80.
    Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). Mar 2003;49(2): 277–300.Google Scholar
  81. 81.
    Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol. Sep 2006;92(1): 60–64.PubMedGoogle Scholar
  82. 82.
    Harris SS. Vitamin D in type 1 diabetes prevention. J Nutr. Feb 2005;135(2): 323–325.PubMedGoogle Scholar
  83. 83.
    Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. May 2005;28(5): 1228–1230.PubMedGoogle Scholar
  84. 84.
    Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia. Jul 2005;48(7): 1247–1257.PubMedGoogle Scholar
  85. 85.
    Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. May 2004;79(5): 820–825.PubMedGoogle Scholar
  86. 86.
    Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. Mar 2008;10(3): 185–197.PubMedGoogle Scholar
  87. 87.
    Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. Sep 2000;72(3): 690–693.PubMedGoogle Scholar
  88. 88.
    Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab. Jul 2005;90(7): 4119–4123.PubMedGoogle Scholar
  89. 89.
    Blum M, Dolnikowski G, Seyoum E, et al. Vitamin D(3) in fat tissue. Endocrine. Feb 2008;33(1): 90–94.PubMedGoogle Scholar
  90. 90.
    Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. Jan 2008;87(1): 136–141.PubMedGoogle Scholar
  91. 91.
    Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. Jan 1 2003;41(1): 105–112.PubMedGoogle Scholar
  92. 92.
    Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. Apr 2001;86(4): 1633–1637.PubMedGoogle Scholar
  93. 93.
    Kalueff AV, Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care. Jan 2007;10(1): 12–19.PubMedCrossRefGoogle Scholar
  94. 94.
    Walbert T, Jirikowski GF, Prufer K. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system of the rat. Horm Metab Res. Sep 2001;33(9): 525–531.PubMedGoogle Scholar
  95. 95.
    Stumpf WE, Sar M, Clark SA, DeLuca HF. Brain target sites for 1,25-dihydroxyvitamin D3. Science. Mar 12 1982;215(4538): 1403–1405.PubMedGoogle Scholar
  96. 96.
    Kuningas M, Mooijaart SP, Jolies J, Slagboom PE, Westendorp RG, van Heemst D. VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging. Aug 20 2007.Google Scholar
  97. 97.
    Gezen-Ak D, Dursun E, Ertan T, et al. Association between vitamin D receptor gene polymorphism and Alzheimer’s disease. Tohoku J Exp Med. Jul 2007;212(3): 275–282.PubMedGoogle Scholar
  98. 98.
    Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D Deficiency Is Associated With Low Mood and Worse Cognitive Performance in Older Adults. Am J Geriatr Psychiatry. Dec 2006; 14(12): 1032–1040.PubMedGoogle Scholar
  99. 99.
    McGrath J, Scragg R, Chant D, Eyles D, Burne T, Obradovic D. No association between serum 25-hydroxyvitamin D3 level and performance on psychometric tests in NHANES HI. Neuroepidemiology. 2007;29(1-2): 49–54.PubMedGoogle Scholar
  100. 100.
    Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. The Tromso study. J Neurol. Apr 2006;253(4): 464–470.PubMedGoogle Scholar
  101. 101.
    Przybelski RJ, Binkley NC. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem Biophys. Apr 15 2007;460(2): 202–205.PubMedGoogle Scholar
  102. 102.
    Cherniack E, Florez H, Hollis B, Roos B, Levis S, Troen B. High Dose of Vitamin D3 Reduces the Prevalence of Hypovitaminosis D in Elderly Veterans. The Gerontologist. October 2007 2007;47(1): 13–14.Google Scholar
  103. 103.
    Ish-Shalom S, Salganik T, Segal E, Raz B, Bromberg I, Vieth R. Daily, Weekly or Monthly Protocols to Reach the Desired Serum 25-Hydroxyvitamin D Concentration for the Elderly. J Bone Miner Res. 2005;20(Suppl 1): S288.Google Scholar
  104. 104.
    Mocanu V, Stitt PA, Costan A, Zbranca E, Luca V, Vieth R. Safety and Bone Mineral Density Effects of Bread Fortified with 125 mcg Vitamin D3/day in Romanian Nnursing-Home Residents. J Bone Miner Res. 2005;20(Suppl 1): S288.Google Scholar
  105. 105.
    Diamond TH, Ho KW, Rohl PG, Meerkin M. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust. Jul 4 2005; 183(1): 10–12.PubMedGoogle Scholar
  106. 106.
    Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. May 1999;69(5): 842–856.PubMedGoogle Scholar
  107. 107.
    Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. Mar 2008;93(3): 677–681.PubMedGoogle Scholar
  108. 108.
    Grant WB, Gorham ED. Commentary: time for public health action on vitamin D for cancer risk reduction. Int J Epidemiol. Apr 2006;35(2): 224–225.PubMedGoogle Scholar
  109. 109.
    Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. Jun 2005;10(2): 94–111.PubMedGoogle Scholar
  110. 110.
    Ramasamy I. Recent advances in physiological calcium homeostasis. Clin Chem Lab Med. 2006;44(3): 237–273.PubMedGoogle Scholar

Copyright information

© Springer-Verlag France and Serdi Éditions 2008

Authors and Affiliations

  • E. P. Cherniack
    • 1
    • 2
    Email author
  • H. Florez
    • 1
    • 2
  • B. A. Roos
    • 1
    • 2
  • B. R. Troen
    • 1
    • 2
  • S. Levis
    • 1
    • 2
  1. 1.Geriatric Research, Education, and Clinical Center and Research ServiceMiami Veterans Affairs Healthcare SystemUSA
  2. 2.Geriatrics Institute and Division of Gerontology and Geriatric Medicine, Department of Medicine, Miller School of MedicineUniversity of MiamiMiami

Personalised recommendations